Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study (AbraxAvast)

This study has been completed.
Sponsor:
Collaborators:
Celgene Corporation
Genentech
Information provided by (Responsible Party):
Lynn E. Spitler, MD, Northern California Melanoma Center
ClinicalTrials.gov Identifier:
NCT00462423
First received: April 18, 2007
Last updated: January 7, 2014
Last verified: January 2014
  Purpose

The study is an open-label, single arm multicenter Phase II study to evaluate the safety and efficacy of the combination of Abraxane and Avastin as first-line therapy for patients with unresectable metastatic malignant melanoma. The patient sample will be approximately 50 individuals, males and females 18 years of age or older with measurable metastatic melanoma.

Patients will be treated with Abraxane administered weekly for 3 weeks via a 30-minute IV infusion at150 mg/m2 followed by 1 week rest (28-day cycle). Avastin will be administered in a dose of 10 mg/kg every 2 weeks (without rest period). Patients will be evaluated for disease progression every 2 months and those who do not have disease progression or unacceptable toxicity will be offered ongoing therapy until they have progressive disease or unacceptable toxicity.


Condition Intervention Phase
Metastatic Malignant Melanoma
Drug: Avastin
Drug: Abraxane
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study

Resource links provided by NLM:


Further study details as provided by Northern California Melanoma Center:

Primary Outcome Measures:
  • Progression-free Survival (PFS) at 4 Months [ Time Frame: 4 months. ] [ Designated as safety issue: No ]
    Progression-free survival at 4 months from first treatment as determined by RECIST 1.0


Secondary Outcome Measures:
  • Progression-free Survival [ Time Frame: From start of treatment to disease progressin; median duration of follow-up for surviving patients was 41.6 months. ] [ Designated as safety issue: No ]
    Median time of progression-free survival from first treatment according to RECIST 1.0

  • Overall Survival (OS) [ Time Frame: April 2007 through December 2010 ] [ Designated as safety issue: No ]
    The duration of overall survival was defined as the number of months between the start date of protocol treatment and the date of death (irrespective of cause), and was right-censored at the date of last contact for patients who were alive as of the data cutoff.

  • Objective Response Rate (RR) in Patients With Measurable Lesions Time to Objective Response [ Time Frame: The median duration of follow-up for surviving patients was 41.6 months. ] [ Designated as safety issue: No ]
    The objective response rate is defined as the percentage of patients showing complete or partial response.

  • Safety and Tolerability of This Combination [ Time Frame: April 2007 through December 2010 ] [ Designated as safety issue: Yes ]
    See adverse events Table


Enrollment: 50
Study Start Date: April 2007
Study Completion Date: January 2012
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm, Open Label
Single Arm, Open Label trial of Abraxane and Avastin
Drug: Avastin
Avastin 10 mg/kg IV every 2 weeks (without rest period).
Other Name: Avastin: bevacizumab.
Drug: Abraxane
Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.

Detailed Description:

It has been suggested that chemotherapy administration may be synergistic with the effects of an antiangiogenic agent such as Avastin. A "Proof of Principal" of the concept of the synergistic effects of chemotherapy and antiangiogenic therapy has been shown in the favorable results reported with temozolomide administered in combination with thalidomide in melanoma, the favorable results reported for the use of FOLFOX4 in combination with Avastin in previously treated patients with advanced or metastatic colorectal cancer, and the approval of the combination of Avastin with 5-fluorouracil-based chemotherapy in the treatment of patients with metastatic carcinoma of the colon or rectum.

A number of lines of evidence suggest that the combination of Abraxane and Avastin may be effective as first-line therapy for melanoma:

  • Taxanes are active agents in melanoma:

    1. In a clinical trial in patients who had failed combination chemotherapy (the Dartmouth regimen, there was a 24% response rate in patients treated with paclitaxel (in combination with tamoxifen).
    2. Paclitaxel is being used in a Phase III trial with carboplatin and Sorafenib in patients with metastatic melanoma who have failed no more than one previous systemic chemotherapeutic treatment.
    3. In a phase II trial of docetaxel in patients with metastatic melanoma, objective responses lasting more than 2 years were observed.
  • Abraxane is a taxane that has efficacy superior to that of Taxol for the treatment of metastatic breast cancer. Abraxane was evaluated as first- and second-line therapy for patients with metastatic melanoma. Results were encouraging. In this study, Abraxane will be combined with Avastin in an effort to improve the clinical benefit and prolong the time to disease progression.

The primary end-point of the study is progression-free survival (PFS) at 4 months. Secondary end-points include progression-free survival, overall survival (OS), objective Response Rate (RR) in patients with measurable lesions, time to objective response, duration of objective response in patients with measurable lesions, and safety and tolerability of this combination.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed, (surgically incurable or unresectable) stage III or IV metastatic malignant melanoma..
  • Must be chemo naïve. Surgical adjuvant therapy with interferon, vaccines, or cytokines is permitted. Prior adjuvant therapy with chemotherapeutic agents is not allowed. Prior therapy for metastatic disease that is not chemotherapy is allowed. Must have discontinued prior allowable therapy at least 4 weeks prior to initiation of dosing.
  • A minimum of 1 measurable lesion according to RECIST criteria.
  • ECOG performance status of 0-1.
  • Age ≥ 18 years.
  • Adequate hematologic, renal and liver function as defined by laboratory values performed within 14 days prior to initiation of dosing.
  • Patients must have recovered from effects of major surgery.
  • Women of childbearing potential should be using an effective method of contraception. Women of childbearing potential must have a negative urine or serum pregnancy test up to 28 days prior to commencement of dosing and be practicing medically approved contraceptive precautions for at least 6 months after completion of treatment as directed by their physician.
  • Men should use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician.
  • Must have recovered from all prior treatment-related toxicities to NCI CTCAE (v 3.0) Grade of 0 or 1, except for toxicities not considered a safety risk such as alopecia.
  • Before study entry, written informed consent must be obtained. Written informed consent must be obtained from the patient prior to performing any study-related procedures.

Exclusion Criteria:

  • Prior systemic therapy for metastatic disease with chemotherapy.
  • Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before trial entry.
  • Major surgery or radiation therapy within 4 weeks of starting the study treatment.
  • Known CNS disease.
  • Previous Grade 2 or higher sensory neuropathy
  • NCI CTCAE (V 3.0) grade 3 hemorrhage within 4 weeks of starting the study treatment.
  • History of or known spinal cord compression, or carcinomatous meningitis, or evidence of symptomatic brain or leptomeningeal disease on screening CT or MRI scan.
  • Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
  • Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade ≥ 2.
  • Inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications)
  • Any prior history of hypertensive crisis or hypertensive encephalopathy
  • Concurrent treatment on another clinical trial. Supportive care trials or non-treatment trials, e.g. QOL, are allowed.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
  • Previous cancer (unless a DRS interval of at least 5 years) or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin.
  • Known clinically uncontrolled infectious disease including HIV positivity or AIDS-related illness.
  • Pregnant or nursing. Use of effective means of contraception (men and women) in subjects of child-bearing potential.
  • New York Heart Association (NYHA) Grade II or greater congestive heart failure.
  • Symptomatic peripheral vascular disease.
  • Significant vascular disease (e.g. aortic aneurysm, aortic dissection).
  • Evidence of bleeding diathesis or coagulopathy.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
  • Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0
  • Proteinuria at screening as demonstrated by urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
  • Serious, non-healing wound, ulcer, or bone fracture
  • Inability to comply with study and/or follow-up procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00462423

Locations
United States, California
Northern California Melanoma Center
San Francisco, California, United States, 94117
The Angeles Clinic and Research Institute
Santa Monica, California, United States, 90404
Sponsors and Collaborators
Lynn E. Spitler, MD
Celgene Corporation
Genentech
Investigators
Principal Investigator: Lynn E. Spitler, MD Northern California Melanoma Center
  More Information

Additional Information:
Publications:
Responsible Party: Lynn E. Spitler, MD, Director, Northern California Melanoma Center
ClinicalTrials.gov Identifier: NCT00462423     History of Changes
Other Study ID Numbers: 070223
Study First Received: April 18, 2007
Results First Received: July 6, 2013
Last Updated: January 7, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Northern California Melanoma Center:
Metastatic malignant melanoma
First-line therapy

Additional relevant MeSH terms:
Melanoma
Nevi and Melanomas
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Paclitaxel
Bevacizumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors

ClinicalTrials.gov processed this record on September 30, 2014